Drugs / G-CSF
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07131280 | Sep 2025 → Jul 2031 expected | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF | “G-CSF will be given at a dose of 5 μg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30” NCT07131280 ↗ |
| Modality | Protein / enzyme biologic | “Growth factors {like GCSF, darbepoetin (EPO) have shown survival benefits with improve liver repair and regeneration” NCT07131280 ↗ |
| Route | Subcutaneous | “G-CSF will be given at a dose of 5 μg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30” NCT07131280 ↗ |